DexCom Croissance future
Future contrôle des critères 4/6
DexCom devrait augmenter ses bénéfices et son chiffre d'affaires de 16.8% et de 13.3% par an respectivement. Le BPA devrait croître de de 16.1% par an. Le rendement des capitaux propres devrait être 24.8% dans 3 ans.
Informations clés
16.8%
Taux de croissance des bénéfices
16.1%
Taux de croissance du BPA
Medical Equipment croissance des bénéfices | 17.1% |
Taux de croissance des recettes | 13.3% |
Rendement futur des capitaux propres | 24.8% |
Couverture par les analystes | Good |
Dernière mise à jour | 22 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?
Nov 08DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings
Oct 21DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Sep 30DexCom: Investors Discounting Long CGM Growth Runway
Sep 19We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
Sep 16DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Apr 25Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price
Apr 12DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Mar 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Mar 04DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital
Jan 15DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing
Jan 01DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Dec 18A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Dec 05At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Nov 21DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
Sep 28DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 5,311 | 953 | 1,001 | 1,358 | 21 |
12/31/2025 | 4,601 | 781 | 798 | 1,137 | 24 |
12/31/2024 | 4,016 | 634 | 603 | 937 | 24 |
9/30/2024 | 3,954 | 681 | 535 | 822 | N/A |
6/30/2024 | 3,935 | 667 | 666 | 891 | N/A |
3/31/2024 | 3,802 | 639 | 584 | 802 | N/A |
12/31/2023 | 3,622 | 542 | 512 | 749 | N/A |
9/30/2023 | 3,403 | 377 | 500 | 747 | N/A |
6/30/2023 | 3,198 | 358 | 466 | 771 | N/A |
3/31/2023 | 3,023 | 293 | 416 | 754 | N/A |
12/31/2022 | 2,910 | 341 | 305 | 670 | N/A |
9/30/2022 | 2,793 | 244 | 261 | 643 | N/A |
6/30/2022 | 2,673 | 230 | 216 | 597 | N/A |
3/31/2022 | 2,572 | 258 | 95 | 486 | N/A |
12/31/2021 | 2,449 | 217 | 53 | 443 | N/A |
9/30/2021 | 2,319 | 577 | 140 | 509 | N/A |
6/30/2021 | 2,170 | 562 | 101 | 409 | N/A |
3/31/2021 | 2,027 | 530 | 236 | 502 | N/A |
12/31/2020 | 1,927 | 550 | 277 | 476 | N/A |
9/30/2020 | 1,821 | 231 | 264 | 447 | N/A |
6/30/2020 | 1,716 | 205 | 209 | 394 | N/A |
3/31/2020 | 1,601 | 148 | 131 | 305 | N/A |
12/31/2019 | 1,476 | 101 | 135 | 315 | N/A |
9/30/2019 | 1,351 | -171 | 51 | 205 | N/A |
6/30/2019 | 1,222 | -170 | 39 | 167 | N/A |
3/31/2019 | 1,128 | -130 | 53 | 144 | N/A |
12/31/2018 | 1,032 | -127 | 56 | 123 | N/A |
9/30/2018 | 915 | 43 | 64 | 131 | N/A |
6/30/2018 | 833 | -5 | N/A | 110 | N/A |
3/31/2018 | 761 | -33 | N/A | 83 | N/A |
12/31/2017 | 719 | -50 | N/A | 92 | N/A |
9/30/2017 | 669 | -48 | N/A | 64 | N/A |
6/30/2017 | 633 | -65 | N/A | 51 | N/A |
3/31/2017 | 599 | -88 | N/A | 57 | N/A |
12/31/2016 | 573 | -66 | N/A | 56 | N/A |
9/30/2016 | 533 | -57 | N/A | 54 | N/A |
6/30/2016 | 490 | -80 | N/A | 49 | N/A |
3/31/2016 | 445 | -64 | N/A | 45 | N/A |
12/31/2015 | 402 | -58 | N/A | 49 | N/A |
9/30/2015 | 356 | -58 | N/A | 46 | N/A |
6/30/2015 | 319 | -20 | N/A | 40 | N/A |
3/31/2015 | 285 | -23 | N/A | 29 | N/A |
12/31/2014 | 259 | -22 | N/A | 24 | N/A |
9/30/2014 | 227 | -26 | N/A | 20 | N/A |
6/30/2014 | 201 | -27 | N/A | 10 | N/A |
3/31/2014 | 178 | -31 | N/A | 5 | N/A |
12/31/2013 | 160 | -30 | N/A | 2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DXCM ( 16.8% par an) est supérieure au taux d'épargne ( 2.6% ).
Bénéfices vs marché: Les bénéfices de DXCM ( 16.8% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).
Croissance élevée des bénéfices: Les bénéfices de DXCM devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DXCM ( 13.3% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DXCM ( 13.3% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de DXCM devrait être élevé dans 3 ans ( 24.8 %)